On-Demand ICS + FABA Combinations in 6–11-Year-Old Children
Loading...
Date
2023
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
In recent years, some new concepts have been added to asthma treatment such as “anti-inflammatory reliever” (β2-agonist use associated to an inhaled corticosteroid (ICS) as a reliever treatment) that combines the benefits of both therapies and provides short- and long-term benefits for treatment in asthma patients. Robust evidence has been presented in patients over 12 years, and the main changes in the international guidelines for asthma treatment were originally made in this age group. However, a few suggestions have been added to treatments in younger patients, in part because of the scarce evidence that exists in this group. We aim to analyze the information regarding the utilization of ICS + fast-acting beta-agonist (FABA) combination in children between 6 and 11 years. Although up until today only three published trials exist (two studies use beclomethasone + albuterol and one study uses budesonide + formoterol), they provide significant information on the benefits of ICS + FABA use in this population.
Description
Keywords
Anti-inflammatory rescue therapy, Asthma treatment, Fast-acting beta-agonist, School children